we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal ...
CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...
Hosted on MSN2mon
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL"Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which achieved durable remission in children with relapsed or refractory B-ALL, including those with isolated and ...
In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom ... Learn about our Editorial Policies. B-cell acute lymphoblastic leukemia is the most ...
The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
Firi-cel is an autologous cell therapy designed to target the cancer protein CD22 ... refractory large B-cell lymphoma (LBCL) that had progressed following treatment with a CD19-targeting CAR ...
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback